(Q37611039)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

Cangrelor: a review on its mechanism of action and clinical development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

3

Dominick J Angiolillo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Masafumi Ueno

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Cardiovascular Therapy

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1195-1201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

ADP receptor antagonism: what's in the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Clinical overview of promising nonthienopyridine antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Central role of the P2Y12 receptor in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Nucleotide receptor signaling in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.101

21 January 2018

Identifiers

DOI

10.1586/ERC.09.101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19814662%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference